Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began

Executive Summary

Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.

You may also be interested in...



ANDA Approvals, Submissions Decline With New Review Goal Coming

Is a rush of generic applications seeking the 10-month clock on the way?

Woodcock's Legacy: CDER Organizational Improvements

In interview with the Pink Sheet, Center for Drug Evaluation and Research director discusses her 30-year career, retirement speculation, and upcoming projects.

Generic User Fee Talks Reach 'Final Wording' But Still Not Done

FDA and industry say they have reached tentative agreement, but finance subgroup says more discussion needed.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel